Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture

Figure 3 Comparison of cumulative survival rates between surgery alone group and surgery combined sorafenib group. Cumulative survival rates in the surgery only group (n = 12, median survival time of 11.41 mo; 95%CI: 6.31-15.49) and in the surgery plus sorafenib group (n = 10, median survival time of 16.47 mo; 95%CI: 7.49-19.72). Cumulative survival rates at 4, 8 and 12 mo tended to be higher in the surgery plus sorafenib group, despite the difference being statistically insignificant (P = 0.18).